nodes	percent_of_prediction	percent_of_DWPC	metapath
Amphetamine—CYP2D6—Lomustine—brain cancer	0.107	0.569	CbGbCtD
Amphetamine—CYP2D6—Hydroxyurea—brain cancer	0.0808	0.431	CbGbCtD
Amphetamine—CARTPT—telencephalic ventricle—brain cancer	0.0469	0.12	CbGeAlD
Amphetamine—CARTPT—hindbrain—brain cancer	0.0221	0.0568	CbGeAlD
Amphetamine—SLC18A2—telencephalic ventricle—brain cancer	0.0159	0.0409	CbGeAlD
Amphetamine—CARTPT—brainstem—brain cancer	0.0127	0.0325	CbGeAlD
Amphetamine—SLC6A3—telencephalic ventricle—brain cancer	0.0121	0.0309	CbGeAlD
Amphetamine—CARTPT—telencephalon—brain cancer	0.0113	0.0289	CbGeAlD
Amphetamine—SLC18A2—Dopaminergic Neurogenesis—OTX2—brain cancer	0.0112	0.0735	CbGpPWpGaD
Amphetamine—CARTPT—Circadian rythm related genes—NTRK3—brain cancer	0.0109	0.0718	CbGpPWpGaD
Amphetamine—SLC18A2—ganglion—brain cancer	0.00992	0.0254	CbGeAlD
Amphetamine—CARTPT—pituitary gland—brain cancer	0.00917	0.0235	CbGeAlD
Amphetamine—DRD2—telencephalic ventricle—brain cancer	0.00886	0.0227	CbGeAlD
Amphetamine—CARTPT—medulla oblongata—brain cancer	0.00885	0.0227	CbGeAlD
Amphetamine—CARTPT—spinal cord—brain cancer	0.00789	0.0202	CbGeAlD
Amphetamine—SLC6A3—ganglion—brain cancer	0.0075	0.0192	CbGeAlD
Amphetamine—CARTPT—endocrine gland—brain cancer	0.0071	0.0182	CbGeAlD
Amphetamine—CARTPT—head—brain cancer	0.00701	0.018	CbGeAlD
Amphetamine—SLC6A4—ganglion—brain cancer	0.00688	0.0176	CbGeAlD
Amphetamine—SLC6A3—Dopaminergic Neurogenesis—OTX2—brain cancer	0.00667	0.0438	CbGpPWpGaD
Amphetamine—MAOB—ganglion—brain cancer	0.00654	0.0168	CbGeAlD
Amphetamine—Digestion impaired—Hydroxyurea—brain cancer	0.00649	0.0251	CcSEcCtD
Amphetamine—TAAR1—central nervous system—brain cancer	0.0064	0.0164	CbGeAlD
Amphetamine—CARTPT—central nervous system—brain cancer	0.0064	0.0164	CbGeAlD
Amphetamine—CYP2A6—CYP2E1 reactions—CYP2C9—brain cancer	0.00636	0.0418	CbGpPWpGaD
Amphetamine—CARTPT—cerebellum—brain cancer	0.00626	0.016	CbGeAlD
Amphetamine—SLC6A2—ganglion—brain cancer	0.00605	0.0155	CbGeAlD
Amphetamine—SLC6A3—hindbrain—brain cancer	0.00569	0.0146	CbGeAlD
Amphetamine—SLC18A2—Synaptic Vesicle Pathway—SYP—brain cancer	0.00554	0.0364	CbGpPWpGaD
Amphetamine—DRD2—ganglion—brain cancer	0.00552	0.0141	CbGeAlD
Amphetamine—Tooth disorder—Temozolomide—brain cancer	0.00522	0.0202	CcSEcCtD
Amphetamine—SLC6A4—hindbrain—brain cancer	0.00522	0.0134	CbGeAlD
Amphetamine—CARTPT—brain—brain cancer	0.00508	0.013	CbGeAlD
Amphetamine—Digestion impaired—Temozolomide—brain cancer	0.00507	0.0196	CcSEcCtD
Amphetamine—MAOB—hindbrain—brain cancer	0.00496	0.0127	CbGeAlD
Amphetamine—SLC18A2—Dopaminergic Neurogenesis—GLI2—brain cancer	0.00487	0.032	CbGpPWpGaD
Amphetamine—SLC22A3—Synaptic Vesicle Pathway—SYP—brain cancer	0.00479	0.0315	CbGpPWpGaD
Amphetamine—Pseudoephedrine—IL2—brain cancer	0.00463	0.37	CrCbGaD
Amphetamine—SLC18A2—Dopaminergic Neurogenesis—GLI1—brain cancer	0.00458	0.0301	CbGpPWpGaD
Amphetamine—SLC6A4—Synaptic Vesicle Pathway—SYP—brain cancer	0.00434	0.0285	CbGpPWpGaD
Amphetamine—SLC18A2—brainstem—brain cancer	0.00431	0.0111	CbGeAlD
Amphetamine—DRD2—hindbrain—brain cancer	0.00418	0.0107	CbGeAlD
Amphetamine—Speech disorder—Carmustine—brain cancer	0.00407	0.0158	CcSEcCtD
Amphetamine—Accidental injury—Carmustine—brain cancer	0.00396	0.0154	CcSEcCtD
Amphetamine—CYP2A6—Xenobiotics—CYP2C9—brain cancer	0.00394	0.0259	CbGpPWpGaD
Amphetamine—Speech disorder—Temozolomide—brain cancer	0.00394	0.0153	CcSEcCtD
Amphetamine—SLC18A2—telencephalon—brain cancer	0.00383	0.00981	CbGeAlD
Amphetamine—CYP2A6—Tamoxifen metabolism—CYP2C9—brain cancer	0.00379	0.0249	CbGpPWpGaD
Amphetamine—Viral infection—Temozolomide—brain cancer	0.00375	0.0145	CcSEcCtD
Amphetamine—Toxic epidermal necrolysis—Procarbazine—brain cancer	0.00366	0.0142	CcSEcCtD
Amphetamine—CARTPT—Circadian rythm related genes—SIRT1—brain cancer	0.00362	0.0238	CbGpPWpGaD
Amphetamine—Infection—Carboplatin—brain cancer	0.00357	0.0139	CcSEcCtD
Amphetamine—CYP2D6—CYP2E1 reactions—CYP2C9—brain cancer	0.00357	0.0234	CbGpPWpGaD
Amphetamine—SLC18A2—Dopaminergic Neurogenesis—SHH—brain cancer	0.00331	0.0218	CbGpPWpGaD
Amphetamine—SLC6A3—brainstem—brain cancer	0.00326	0.00836	CbGeAlD
Amphetamine—Photosensitivity reaction—Procarbazine—brain cancer	0.00321	0.0124	CcSEcCtD
Amphetamine—Infection—Lomustine—brain cancer	0.00313	0.0121	CcSEcCtD
Amphetamine—SLC18A2—medulla oblongata—brain cancer	0.00301	0.00771	CbGeAlD
Amphetamine—Sweating—Procarbazine—brain cancer	0.003	0.0116	CcSEcCtD
Amphetamine—Anorexia—Lomustine—brain cancer	0.003	0.0116	CcSEcCtD
Amphetamine—SLC6A4—brainstem—brain cancer	0.00299	0.00766	CbGeAlD
Amphetamine—SLC6A3—Dopaminergic Neurogenesis—GLI2—brain cancer	0.0029	0.0191	CbGpPWpGaD
Amphetamine—SLC6A3—telencephalon—brain cancer	0.00289	0.00742	CbGeAlD
Amphetamine—Body temperature increased—Carboplatin—brain cancer	0.00284	0.011	CcSEcCtD
Amphetamine—MAOB—brainstem—brain cancer	0.00284	0.00729	CbGeAlD
Amphetamine—Injury—Carmustine—brain cancer	0.00277	0.0107	CcSEcCtD
Amphetamine—SLC18A2—midbrain—brain cancer	0.00275	0.00705	CbGeAlD
Amphetamine—CARTPT—Circadian rythm related genes—CDK4—brain cancer	0.00274	0.018	CbGpPWpGaD
Amphetamine—Decreased appetite—Lomustine—brain cancer	0.00274	0.0106	CcSEcCtD
Amphetamine—SLC6A3—Dopaminergic Neurogenesis—GLI1—brain cancer	0.00273	0.0179	CbGpPWpGaD
Amphetamine—MAOB—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.00272	0.0179	CbGpPWpGaD
Amphetamine—CYP2A6—Constitutive Androstane Receptor Pathway—CYP2C9—brain cancer	0.00271	0.0178	CbGpPWpGaD
Amphetamine—SLC6A4—telencephalon—brain cancer	0.00265	0.0068	CbGeAlD
Amphetamine—SLC6A2—brainstem—brain cancer	0.00263	0.00675	CbGeAlD
Amphetamine—MAOB—telencephalon—brain cancer	0.00252	0.00647	CbGeAlD
Amphetamine—CYP2D6—hindbrain—brain cancer	0.00251	0.00645	CbGeAlD
Amphetamine—Body temperature increased—Lomustine—brain cancer	0.00249	0.00965	CcSEcCtD
Amphetamine—Affect lability—Temozolomide—brain cancer	0.00242	0.00938	CcSEcCtD
Amphetamine—SLC18A2—endocrine gland—brain cancer	0.00241	0.00619	CbGeAlD
Amphetamine—Tension—Procarbazine—brain cancer	0.0024	0.00932	CcSEcCtD
Amphetamine—DRD2—brainstem—brain cancer	0.0024	0.00615	CbGeAlD
Amphetamine—SLC18A2—head—brain cancer	0.00238	0.00611	CbGeAlD
Amphetamine—Tranylcypromine—CYP2C9—brain cancer	0.00238	0.19	CrCbGaD
Amphetamine—Nervousness—Procarbazine—brain cancer	0.00238	0.00922	CcSEcCtD
Amphetamine—SLC6A2—telencephalon—brain cancer	0.00234	0.00599	CbGeAlD
Amphetamine—Mood swings—Temozolomide—brain cancer	0.00233	0.00903	CcSEcCtD
Amphetamine—Tremor—Procarbazine—brain cancer	0.00229	0.0089	CcSEcCtD
Amphetamine—SLC22A3—gonad—brain cancer	0.00227	0.00583	CbGeAlD
Amphetamine—Toxic epidermal necrolysis—Temozolomide—brain cancer	0.00221	0.00858	CcSEcCtD
Amphetamine—CYP2D6—Xenobiotics—CYP2C9—brain cancer	0.00221	0.0145	CbGpPWpGaD
Amphetamine—SLC18A2—central nervous system—brain cancer	0.00218	0.00558	CbGeAlD
Amphetamine—DRD2—telencephalon—brain cancer	0.00213	0.00546	CbGeAlD
Amphetamine—CYP2D6—Tamoxifen metabolism—CYP2C9—brain cancer	0.00213	0.014	CbGpPWpGaD
Amphetamine—SLC18A2—cerebellum—brain cancer	0.00213	0.00545	CbGeAlD
Amphetamine—Convulsion—Procarbazine—brain cancer	0.00212	0.00823	CcSEcCtD
Amphetamine—Hypertension—Procarbazine—brain cancer	0.00211	0.0082	CcSEcCtD
Amphetamine—SLC6A3—midbrain—brain cancer	0.00208	0.00533	CbGeAlD
Amphetamine—Anxiety—Procarbazine—brain cancer	0.00208	0.00806	CcSEcCtD
Amphetamine—MAOB—pituitary gland—brain cancer	0.00205	0.00527	CbGeAlD
Amphetamine—Dry mouth—Procarbazine—brain cancer	0.00204	0.00791	CcSEcCtD
Amphetamine—SLC6A3—spinal cord—brain cancer	0.00203	0.0052	CbGeAlD
Amphetamine—Vomiting—Lomustine—brain cancer	0.002	0.00776	CcSEcCtD
Amphetamine—Phentermine—CYP2C9—brain cancer	0.002	0.16	CrCbGaD
Amphetamine—Infection—Procarbazine—brain cancer	0.00199	0.0077	CcSEcCtD
Amphetamine—MAOB—medulla oblongata—brain cancer	0.00198	0.00508	CbGeAlD
Amphetamine—SLC6A3—Dopaminergic Neurogenesis—SHH—brain cancer	0.00197	0.013	CbGpPWpGaD
Amphetamine—Erectile dysfunction—Temozolomide—brain cancer	0.00196	0.00759	CcSEcCtD
Amphetamine—Depression—Carmustine—brain cancer	0.00195	0.00758	CcSEcCtD
Amphetamine—Tachycardia—Procarbazine—brain cancer	0.00195	0.00756	CcSEcCtD
Amphetamine—SLC6A2—gonad—brain cancer	0.00195	0.005	CbGeAlD
Amphetamine—Photosensitivity reaction—Temozolomide—brain cancer	0.00194	0.00752	CcSEcCtD
Amphetamine—Hyperhidrosis—Procarbazine—brain cancer	0.00193	0.00749	CcSEcCtD
Amphetamine—Weight decreased—Temozolomide—brain cancer	0.00192	0.00745	CcSEcCtD
Amphetamine—Urinary tract infection—Carmustine—brain cancer	0.00191	0.00739	CcSEcCtD
Amphetamine—Anorexia—Procarbazine—brain cancer	0.00191	0.00739	CcSEcCtD
Amphetamine—SLC6A4—midbrain—brain cancer	0.00191	0.00488	CbGeAlD
Amphetamine—CYP2A6—cerebellum—brain cancer	0.0019	0.00487	CbGeAlD
Amphetamine—Depression—Temozolomide—brain cancer	0.00189	0.00733	CcSEcCtD
Amphetamine—Stevens-Johnson syndrome—Temozolomide—brain cancer	0.00188	0.00728	CcSEcCtD
Amphetamine—Nausea—Lomustine—brain cancer	0.00187	0.00725	CcSEcCtD
Amphetamine—SLC6A4—spinal cord—brain cancer	0.00186	0.00477	CbGeAlD
Amphetamine—Selegiline—CYP2C9—brain cancer	0.00185	0.148	CrCbGaD
Amphetamine—Urinary tract infection—Temozolomide—brain cancer	0.00184	0.00714	CcSEcCtD
Amphetamine—SLC6A2—medulla oblongata—brain cancer	0.00184	0.00471	CbGeAlD
Amphetamine—MAOB—midbrain—brain cancer	0.00181	0.00464	CbGeAlD
Amphetamine—Insomnia—Procarbazine—brain cancer	0.00181	0.00701	CcSEcCtD
Amphetamine—SLC6A3—head—brain cancer	0.0018	0.00462	CbGeAlD
Amphetamine—Somnolence—Procarbazine—brain cancer	0.00178	0.00689	CcSEcCtD
Amphetamine—Toxic epidermal necrolysis—Etoposide—brain cancer	0.00177	0.00687	CcSEcCtD
Amphetamine—MAOB—spinal cord—brain cancer	0.00177	0.00453	CbGeAlD
Amphetamine—Decreased appetite—Procarbazine—brain cancer	0.00174	0.00674	CcSEcCtD
Amphetamine—DRD2—pituitary gland—brain cancer	0.00173	0.00444	CbGeAlD
Amphetamine—SLC18A2—brain—brain cancer	0.00173	0.00443	CbGeAlD
Amphetamine—Fatigue—Procarbazine—brain cancer	0.00172	0.00668	CcSEcCtD
Amphetamine—SLC22A3—endocrine gland—brain cancer	0.00172	0.00441	CbGeAlD
Amphetamine—Constipation—Procarbazine—brain cancer	0.00171	0.00663	CcSEcCtD
Amphetamine—SLC22A3—head—brain cancer	0.0017	0.00435	CbGeAlD
Amphetamine—SLC6A4—endocrine gland—brain cancer	0.00167	0.00429	CbGeAlD
Amphetamine—SLC6A4—head—brain cancer	0.00165	0.00424	CbGeAlD
Amphetamine—Nateglinide—CYP2C9—brain cancer	0.00165	0.132	CrCbGaD
Amphetamine—SLC6A3—central nervous system—brain cancer	0.00165	0.00422	CbGeAlD
Amphetamine—Convulsion—Hydroxyurea—brain cancer	0.00164	0.00637	CcSEcCtD
Amphetamine—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.00164	0.0108	CbGpPWpGaD
Amphetamine—Gastrointestinal pain—Procarbazine—brain cancer	0.00163	0.00634	CcSEcCtD
Amphetamine—CYP2A6—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.00162	0.0106	CbGpPWpGaD
Amphetamine—SLC22A5—pituitary gland—brain cancer	0.00161	0.00414	CbGeAlD
Amphetamine—SLC6A3—cerebellum—brain cancer	0.00161	0.00412	CbGeAlD
Amphetamine—Erythema multiforme—Temozolomide—brain cancer	0.00161	0.00624	CcSEcCtD
Amphetamine—MAOB—endocrine gland—brain cancer	0.00159	0.00408	CbGeAlD
Amphetamine—Urticaria—Procarbazine—brain cancer	0.00159	0.00616	CcSEcCtD
Amphetamine—Abdominal pain—Procarbazine—brain cancer	0.00158	0.00613	CcSEcCtD
Amphetamine—Body temperature increased—Procarbazine—brain cancer	0.00158	0.00613	CcSEcCtD
Amphetamine—MAOB—head—brain cancer	0.00157	0.00403	CbGeAlD
Amphetamine—SLC22A5—medulla oblongata—brain cancer	0.00156	0.00399	CbGeAlD
Amphetamine—SLC22A3—central nervous system—brain cancer	0.00155	0.00397	CbGeAlD
Amphetamine—CYP2A6—brain—brain cancer	0.00154	0.00395	CbGeAlD
Amphetamine—TAAR1—GPCR ligand binding—PTCH2—brain cancer	0.00154	0.0101	CbGpPWpGaD
Amphetamine—Infection—Hydroxyurea—brain cancer	0.00154	0.00596	CcSEcCtD
Amphetamine—DRD2—midbrain—brain cancer	0.00153	0.00392	CbGeAlD
Amphetamine—SLC6A4—central nervous system—brain cancer	0.00151	0.00387	CbGeAlD
Amphetamine—Stevens-Johnson syndrome—Etoposide—brain cancer	0.0015	0.00583	CcSEcCtD
Amphetamine—Acute coronary syndrome—Etoposide—brain cancer	0.00149	0.0058	CcSEcCtD
Amphetamine—Myocardial infarction—Etoposide—brain cancer	0.00149	0.00576	CcSEcCtD
Amphetamine—Anorexia—Hydroxyurea—brain cancer	0.00147	0.00572	CcSEcCtD
Amphetamine—SLC6A2—endocrine gland—brain cancer	0.00147	0.00378	CbGeAlD
Amphetamine—Hypersensitivity—Procarbazine—brain cancer	0.00147	0.00571	CcSEcCtD
Amphetamine—SLC6A2—head—brain cancer	0.00145	0.00373	CbGeAlD
Amphetamine—MAOB—Biological oxidations—CYP2C9—brain cancer	0.00145	0.00951	CbGpPWpGaD
Amphetamine—CYP2D6—brainstem—brain cancer	0.00144	0.00369	CbGeAlD
Amphetamine—Tremor—Carmustine—brain cancer	0.00144	0.00557	CcSEcCtD
Amphetamine—Asthenia—Procarbazine—brain cancer	0.00143	0.00556	CcSEcCtD
Amphetamine—MAOB—central nervous system—brain cancer	0.00143	0.00368	CbGeAlD
Amphetamine—SLC22A5—midbrain—brain cancer	0.00142	0.00365	CbGeAlD
Amphetamine—Agitation—Carmustine—brain cancer	0.00141	0.00546	CcSEcCtD
Amphetamine—MAOB—cerebellum—brain cancer	0.0014	0.00359	CbGeAlD
Amphetamine—SLC22A5—spinal cord—brain cancer	0.00139	0.00356	CbGeAlD
Amphetamine—Tremor—Temozolomide—brain cancer	0.00139	0.00538	CcSEcCtD
Amphetamine—Dyspnoea—Hydroxyurea—brain cancer	0.00138	0.00535	CcSEcCtD
Amphetamine—Somnolence—Hydroxyurea—brain cancer	0.00138	0.00533	CcSEcCtD
Amphetamine—Diarrhoea—Procarbazine—brain cancer	0.00137	0.0053	CcSEcCtD
Amphetamine—Dyspepsia—Hydroxyurea—brain cancer	0.00136	0.00528	CcSEcCtD
Amphetamine—Agitation—Temozolomide—brain cancer	0.00136	0.00528	CcSEcCtD
Amphetamine—Angioedema—Temozolomide—brain cancer	0.00135	0.00525	CcSEcCtD
Amphetamine—TAAR1—GPCR downstream signaling—OR4C12—brain cancer	0.00135	0.00887	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—OR14C36—brain cancer	0.00135	0.00887	CbGpPWpGaD
Amphetamine—Decreased appetite—Hydroxyurea—brain cancer	0.00134	0.00521	CcSEcCtD
Amphetamine—DRD2—endocrine gland—brain cancer	0.00134	0.00344	CbGeAlD
Amphetamine—Gastrointestinal disorder—Hydroxyurea—brain cancer	0.00134	0.00518	CcSEcCtD
Amphetamine—Fatigue—Hydroxyurea—brain cancer	0.00133	0.00517	CcSEcCtD
Amphetamine—SLC6A2—central nervous system—brain cancer	0.00133	0.0034	CbGeAlD
Amphetamine—Convulsion—Carmustine—brain cancer	0.00133	0.00515	CcSEcCtD
Amphetamine—CYP2A6—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.00133	0.00872	CbGpPWpGaD
Amphetamine—DRD2—head—brain cancer	0.00133	0.0034	CbGeAlD
Amphetamine—Hypertension—Carmustine—brain cancer	0.00132	0.00513	CcSEcCtD
Amphetamine—Constipation—Hydroxyurea—brain cancer	0.00132	0.00513	CcSEcCtD
Amphetamine—Dizziness—Procarbazine—brain cancer	0.00132	0.00512	CcSEcCtD
Amphetamine—Palpitations—Temozolomide—brain cancer	0.00131	0.00507	CcSEcCtD
Amphetamine—SLC6A3—brain—brain cancer	0.00131	0.00335	CbGeAlD
Amphetamine—Chest pain—Carmustine—brain cancer	0.0013	0.00506	CcSEcCtD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—HES5—brain cancer	0.0013	0.00856	CbGpPWpGaD
Amphetamine—Anxiety—Carmustine—brain cancer	0.0013	0.00504	CcSEcCtD
Amphetamine—Erythema multiforme—Etoposide—brain cancer	0.00129	0.00499	CcSEcCtD
Amphetamine—Convulsion—Temozolomide—brain cancer	0.00128	0.00497	CcSEcCtD
Amphetamine—CYP2D6—telencephalon—brain cancer	0.00128	0.00328	CbGeAlD
Amphetamine—Hypertension—Temozolomide—brain cancer	0.00128	0.00496	CcSEcCtD
Amphetamine—Vomiting—Procarbazine—brain cancer	0.00127	0.00493	CcSEcCtD
Amphetamine—Rash—Procarbazine—brain cancer	0.00126	0.00489	CcSEcCtD
Amphetamine—Dermatitis—Procarbazine—brain cancer	0.00126	0.00488	CcSEcCtD
Amphetamine—Anxiety—Temozolomide—brain cancer	0.00126	0.00487	CcSEcCtD
Amphetamine—Headache—Procarbazine—brain cancer	0.00125	0.00486	CcSEcCtD
Amphetamine—Infection—Carmustine—brain cancer	0.00124	0.00482	CcSEcCtD
Amphetamine—Dry mouth—Temozolomide—brain cancer	0.00123	0.00478	CcSEcCtD
Amphetamine—SLC22A3—brain—brain cancer	0.00123	0.00315	CbGeAlD
Amphetamine—TAAR1—Signaling by GPCR—OR4C12—brain cancer	0.00123	0.00805	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—OR14C36—brain cancer	0.00123	0.00805	CbGpPWpGaD
Amphetamine—Body temperature increased—Hydroxyurea—brain cancer	0.00122	0.00474	CcSEcCtD
Amphetamine—Tachycardia—Carmustine—brain cancer	0.00122	0.00473	CcSEcCtD
Amphetamine—DRD2—central nervous system—brain cancer	0.00121	0.0031	CbGeAlD
Amphetamine—Anaphylactic shock—Temozolomide—brain cancer	0.00121	0.00469	CcSEcCtD
Amphetamine—Infection—Temozolomide—brain cancer	0.0012	0.00466	CcSEcCtD
Amphetamine—SLC6A4—brain—brain cancer	0.0012	0.00307	CbGeAlD
Amphetamine—Anorexia—Carmustine—brain cancer	0.00119	0.00462	CcSEcCtD
Amphetamine—Nausea—Procarbazine—brain cancer	0.00119	0.0046	CcSEcCtD
Amphetamine—DRD2—cerebellum—brain cancer	0.00118	0.00303	CbGeAlD
Amphetamine—Hyperhidrosis—Temozolomide—brain cancer	0.00117	0.00453	CcSEcCtD
Amphetamine—CARTPT—Circadian rythm related genes—TP53—brain cancer	0.00117	0.00766	CbGpPWpGaD
Amphetamine—Anorexia—Temozolomide—brain cancer	0.00115	0.00447	CcSEcCtD
Amphetamine—Hypersensitivity—Hydroxyurea—brain cancer	0.00114	0.00442	CcSEcCtD
Amphetamine—MAOB—brain—brain cancer	0.00114	0.00292	CbGeAlD
Amphetamine—Insomnia—Carmustine—brain cancer	0.00113	0.00439	CcSEcCtD
Amphetamine—Dyspnoea—Carmustine—brain cancer	0.00111	0.00432	CcSEcCtD
Amphetamine—Somnolence—Carmustine—brain cancer	0.00111	0.00431	CcSEcCtD
Amphetamine—Asthenia—Hydroxyurea—brain cancer	0.00111	0.0043	CcSEcCtD
Amphetamine—SLC22A5—cerebellum—brain cancer	0.0011	0.00282	CbGeAlD
Amphetamine—SLC6A4—Circadian rythm related genes—NTRK3—brain cancer	0.0011	0.00721	CbGpPWpGaD
Amphetamine—Insomnia—Temozolomide—brain cancer	0.00109	0.00424	CcSEcCtD
Amphetamine—Decreased appetite—Carmustine—brain cancer	0.00109	0.00421	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Carmustine—brain cancer	0.00108	0.00419	CcSEcCtD
Amphetamine—Dyspnoea—Temozolomide—brain cancer	0.00108	0.00418	CcSEcCtD
Amphetamine—Somnolence—Temozolomide—brain cancer	0.00107	0.00417	CcSEcCtD
Amphetamine—Constipation—Carmustine—brain cancer	0.00107	0.00415	CcSEcCtD
Amphetamine—Dyspepsia—Temozolomide—brain cancer	0.00106	0.00412	CcSEcCtD
Amphetamine—Diarrhoea—Hydroxyurea—brain cancer	0.00106	0.0041	CcSEcCtD
Amphetamine—SLC6A2—brain—brain cancer	0.00105	0.0027	CbGeAlD
Amphetamine—Decreased appetite—Temozolomide—brain cancer	0.00105	0.00407	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Temozolomide—brain cancer	0.00104	0.00405	CcSEcCtD
Amphetamine—Fatigue—Temozolomide—brain cancer	0.00104	0.00404	CcSEcCtD
Amphetamine—SLC6A3—Parkinsons Disease Pathway—CCNE1—brain cancer	0.00104	0.00683	CbGpPWpGaD
Amphetamine—Constipation—Temozolomide—brain cancer	0.00103	0.00401	CcSEcCtD
Amphetamine—Convulsion—Etoposide—brain cancer	0.00103	0.00398	CcSEcCtD
Amphetamine—Hypertension—Etoposide—brain cancer	0.00102	0.00397	CcSEcCtD
Amphetamine—Dizziness—Hydroxyurea—brain cancer	0.00102	0.00397	CcSEcCtD
Amphetamine—Gastrointestinal pain—Carmustine—brain cancer	0.00102	0.00396	CcSEcCtD
Amphetamine—Chest pain—Etoposide—brain cancer	0.00101	0.00391	CcSEcCtD
Amphetamine—Body temperature increased—Carmustine—brain cancer	0.000988	0.00383	CcSEcCtD
Amphetamine—Abdominal pain—Carmustine—brain cancer	0.000988	0.00383	CcSEcCtD
Amphetamine—Gastrointestinal pain—Temozolomide—brain cancer	0.000988	0.00383	CcSEcCtD
Amphetamine—Vomiting—Hydroxyurea—brain cancer	0.000983	0.00381	CcSEcCtD
Amphetamine—Rash—Hydroxyurea—brain cancer	0.000975	0.00378	CcSEcCtD
Amphetamine—Dermatitis—Hydroxyurea—brain cancer	0.000974	0.00378	CcSEcCtD
Amphetamine—Headache—Hydroxyurea—brain cancer	0.000969	0.00376	CcSEcCtD
Amphetamine—Anaphylactic shock—Etoposide—brain cancer	0.000967	0.00375	CcSEcCtD
Amphetamine—Infection—Etoposide—brain cancer	0.000961	0.00372	CcSEcCtD
Amphetamine—DRD2—brain—brain cancer	0.00096	0.00246	CbGeAlD
Amphetamine—Urticaria—Temozolomide—brain cancer	0.00096	0.00372	CcSEcCtD
Amphetamine—Abdominal pain—Temozolomide—brain cancer	0.000955	0.0037	CcSEcCtD
Amphetamine—Body temperature increased—Temozolomide—brain cancer	0.000955	0.0037	CcSEcCtD
Amphetamine—Tachycardia—Etoposide—brain cancer	0.000944	0.00366	CcSEcCtD
Amphetamine—Hyperhidrosis—Etoposide—brain cancer	0.000935	0.00362	CcSEcCtD
Amphetamine—Anorexia—Etoposide—brain cancer	0.000922	0.00357	CcSEcCtD
Amphetamine—Hypersensitivity—Carmustine—brain cancer	0.000921	0.00357	CcSEcCtD
Amphetamine—Nausea—Hydroxyurea—brain cancer	0.000919	0.00356	CcSEcCtD
Amphetamine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.000918	0.00604	CbGpPWpGaD
Amphetamine—CYP2D6—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.000906	0.00596	CbGpPWpGaD
Amphetamine—SLC18A2—Dopaminergic Neurogenesis—STAT3—brain cancer	0.000899	0.00591	CbGpPWpGaD
Amphetamine—Asthenia—Carmustine—brain cancer	0.000897	0.00348	CcSEcCtD
Amphetamine—SLC22A5—brain—brain cancer	0.000894	0.00229	CbGeAlD
Amphetamine—Hypersensitivity—Temozolomide—brain cancer	0.00089	0.00345	CcSEcCtD
Amphetamine—Asthenia—Temozolomide—brain cancer	0.000867	0.00336	CcSEcCtD
Amphetamine—Dyspnoea—Etoposide—brain cancer	0.000862	0.00334	CcSEcCtD
Amphetamine—Somnolence—Etoposide—brain cancer	0.00086	0.00333	CcSEcCtD
Amphetamine—Diarrhoea—Carmustine—brain cancer	0.000856	0.00332	CcSEcCtD
Amphetamine—Decreased appetite—Etoposide—brain cancer	0.000841	0.00326	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Etoposide—brain cancer	0.000835	0.00324	CcSEcCtD
Amphetamine—Fatigue—Etoposide—brain cancer	0.000834	0.00323	CcSEcCtD
Amphetamine—Dizziness—Carmustine—brain cancer	0.000827	0.00321	CcSEcCtD
Amphetamine—Constipation—Etoposide—brain cancer	0.000827	0.00321	CcSEcCtD
Amphetamine—Diarrhoea—Temozolomide—brain cancer	0.000827	0.00321	CcSEcCtD
Amphetamine—CYP2D6—endocrine gland—brain cancer	0.000807	0.00207	CbGeAlD
Amphetamine—Dizziness—Temozolomide—brain cancer	0.000799	0.0031	CcSEcCtD
Amphetamine—CYP2D6—head—brain cancer	0.000796	0.00204	CbGeAlD
Amphetamine—Vomiting—Carmustine—brain cancer	0.000795	0.00308	CcSEcCtD
Amphetamine—TAAR1—GPCR ligand binding—SHH—brain cancer	0.000792	0.00521	CbGpPWpGaD
Amphetamine—Gastrointestinal pain—Etoposide—brain cancer	0.000791	0.00307	CcSEcCtD
Amphetamine—TAAR1—Signaling by GPCR—PTCH2—brain cancer	0.000789	0.00519	CbGpPWpGaD
Amphetamine—Rash—Carmustine—brain cancer	0.000788	0.00306	CcSEcCtD
Amphetamine—Dermatitis—Carmustine—brain cancer	0.000788	0.00305	CcSEcCtD
Amphetamine—Headache—Carmustine—brain cancer	0.000783	0.00304	CcSEcCtD
Amphetamine—Vomiting—Temozolomide—brain cancer	0.000768	0.00298	CcSEcCtD
Amphetamine—Urticaria—Etoposide—brain cancer	0.000768	0.00298	CcSEcCtD
Amphetamine—Abdominal pain—Etoposide—brain cancer	0.000764	0.00296	CcSEcCtD
Amphetamine—Body temperature increased—Etoposide—brain cancer	0.000764	0.00296	CcSEcCtD
Amphetamine—Rash—Temozolomide—brain cancer	0.000762	0.00295	CcSEcCtD
Amphetamine—Dermatitis—Temozolomide—brain cancer	0.000761	0.00295	CcSEcCtD
Amphetamine—Headache—Temozolomide—brain cancer	0.000757	0.00294	CcSEcCtD
Amphetamine—TAAR1—GPCR ligand binding—SMO—brain cancer	0.000751	0.00494	CbGpPWpGaD
Amphetamine—TAAR1—GPCR ligand binding—PTCH1—brain cancer	0.000751	0.00494	CbGpPWpGaD
Amphetamine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—brain cancer	0.000747	0.00491	CbGpPWpGaD
Amphetamine—CYP2D6—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.000744	0.00489	CbGpPWpGaD
Amphetamine—Nausea—Carmustine—brain cancer	0.000743	0.00288	CcSEcCtD
Amphetamine—CYP2D6—central nervous system—brain cancer	0.000727	0.00186	CbGeAlD
Amphetamine—TAAR1—Signaling Pathways—OR4C12—brain cancer	0.000724	0.00476	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—OR14C36—brain cancer	0.000724	0.00476	CbGpPWpGaD
Amphetamine—Nausea—Temozolomide—brain cancer	0.000718	0.00278	CcSEcCtD
Amphetamine—Hypersensitivity—Etoposide—brain cancer	0.000712	0.00276	CcSEcCtD
Amphetamine—CYP2D6—cerebellum—brain cancer	0.00071	0.00182	CbGeAlD
Amphetamine—CYP2A6—Biological oxidations—CYP2C9—brain cancer	0.000705	0.00463	CbGpPWpGaD
Amphetamine—Asthenia—Etoposide—brain cancer	0.000694	0.00269	CcSEcCtD
Amphetamine—TAAR1—GPCR downstream signaling—ABR—brain cancer	0.000682	0.00448	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—NTRK3—brain cancer	0.000671	0.00441	CbGpPWpGaD
Amphetamine—Diarrhoea—Etoposide—brain cancer	0.000662	0.00257	CcSEcCtD
Amphetamine—Dizziness—Etoposide—brain cancer	0.000639	0.00248	CcSEcCtD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—S100A10—brain cancer	0.000624	0.0041	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—ABR—brain cancer	0.000619	0.00407	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—DTX2—brain cancer	0.000615	0.00404	CbGpPWpGaD
Amphetamine—Vomiting—Etoposide—brain cancer	0.000615	0.00238	CcSEcCtD
Amphetamine—Rash—Etoposide—brain cancer	0.00061	0.00236	CcSEcCtD
Amphetamine—Dermatitis—Etoposide—brain cancer	0.000609	0.00236	CcSEcCtD
Amphetamine—Headache—Etoposide—brain cancer	0.000606	0.00235	CcSEcCtD
Amphetamine—CYP2D6—brain—brain cancer	0.000577	0.00148	CbGeAlD
Amphetamine—Nausea—Etoposide—brain cancer	0.000574	0.00223	CcSEcCtD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—ESR2—brain cancer	0.000554	0.00364	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—S100A10—brain cancer	0.00054	0.00355	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—S100A10—brain cancer	0.000538	0.00354	CbGpPWpGaD
Amphetamine—SLC6A3—Dopaminergic Neurogenesis—STAT3—brain cancer	0.000536	0.00352	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—PTCH2—brain cancer	0.000466	0.00307	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—HES5—brain cancer	0.000452	0.00297	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—STRADA—brain cancer	0.000438	0.00288	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—TRPC6—brain cancer	0.000432	0.00284	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—HES1—brain cancer	0.00043	0.00283	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—S100A10—brain cancer	0.00042	0.00276	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—SHH—brain cancer	0.000407	0.00267	CbGpPWpGaD
Amphetamine—CYP2D6—Biological oxidations—CYP2C9—brain cancer	0.000395	0.0026	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—TRPC6—brain cancer	0.000392	0.00258	CbGpPWpGaD
Amphetamine—CYP2D6—Metapathway biotransformation—CYP2C9—brain cancer	0.00039	0.00256	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—PTCH1—brain cancer	0.000386	0.00253	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—SMO—brain cancer	0.000386	0.00253	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—S100A10—brain cancer	0.000372	0.00244	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—ABR—brain cancer	0.000366	0.00241	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—SIRT1—brain cancer	0.000364	0.00239	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—PTCH2—brain cancer	0.000359	0.00236	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—GLI2—brain cancer	0.000353	0.00232	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—GLI1—brain cancer	0.000332	0.00218	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—VAV1—brain cancer	0.000324	0.00213	CbGpPWpGaD
Amphetamine—CYP2A6—Fluoropyrimidine Activity—TP53—brain cancer	0.000317	0.00208	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—SUFU—brain cancer	0.000315	0.00207	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—OR4C12—brain cancer	0.000315	0.00207	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—OR14C36—brain cancer	0.000315	0.00207	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—GFAP—brain cancer	0.000304	0.002	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—VAV1—brain cancer	0.000294	0.00193	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—TRPC6—brain cancer	0.000288	0.00189	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—HEY1—brain cancer	0.000288	0.00189	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—OR4C12—brain cancer	0.000286	0.00188	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—OR14C36—brain cancer	0.000286	0.00188	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—DLL1—brain cancer	0.000283	0.00186	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—CDK4—brain cancer	0.000276	0.00181	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—TRPC6—brain cancer	0.000249	0.00164	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—TRPC6—brain cancer	0.000248	0.00163	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—CYP2C9—brain cancer	0.000248	0.00163	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—SHH—brain cancer	0.00024	0.00158	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—TRPC6—brain cancer	0.000232	0.00152	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—SMO—brain cancer	0.000228	0.0015	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—PTCH1—brain cancer	0.000228	0.0015	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—SIRT1—brain cancer	0.000223	0.00146	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—CTNNB1—brain cancer	0.000216	0.00142	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—BSG—brain cancer	0.00021	0.00138	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—CYP2C9—brain cancer	0.000209	0.00138	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—PIK3CG—brain cancer	0.000205	0.00135	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—TRPC6—brain cancer	0.000194	0.00127	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—VEGFA—brain cancer	0.00019	0.00125	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—PIK3CG—brain cancer	0.000187	0.00123	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—SHH—brain cancer	0.000185	0.00121	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—PTCH2—brain cancer	0.000184	0.00121	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—NOTCH2—brain cancer	0.000182	0.0012	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—IDH1—brain cancer	0.000181	0.00119	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—BSG—brain cancer	0.000178	0.00117	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—SMO—brain cancer	0.000175	0.00115	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—PTCH1—brain cancer	0.000175	0.00115	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—VAV1—brain cancer	0.000174	0.00114	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—TRPC6—brain cancer	0.000172	0.00113	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—OR4C12—brain cancer	0.000169	0.00111	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—OR14C36—brain cancer	0.000169	0.00111	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—CDK4—brain cancer	0.000169	0.00111	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—ABR—brain cancer	0.000159	0.00105	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—IDH1—brain cancer	0.000153	0.00101	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—HES1—brain cancer	0.000149	0.000981	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—IL2—brain cancer	0.000145	0.00095	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—ABR—brain cancer	0.000144	0.00095	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—DTX2—brain cancer	0.000144	0.000943	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—ENO2—brain cancer	0.000143	0.00094	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—PDGFRA—brain cancer	0.000142	0.000934	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—SPP1—brain cancer	0.000138	0.000907	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—IL2—brain cancer	0.000131	0.000863	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—IRS2—brain cancer	0.000125	0.00082	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—ENO2—brain cancer	0.000121	0.000796	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CYP2C9—brain cancer	0.000121	0.000793	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—TP53—brain cancer	0.000117	0.00077	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—PIK3CG—brain cancer	0.00011	0.000724	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—APC—brain cancer	0.00011	0.000724	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PTCH2—brain cancer	0.000109	0.000715	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—HES5—brain cancer	0.000105	0.000692	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—BSG—brain cancer	0.000103	0.000674	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—STRADA—brain cancer	0.000102	0.000672	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—TRPC6—brain cancer	0.000101	0.000662	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—EGFR—brain cancer	0.0001	0.00066	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—SHH—brain cancer	9.48e-05	0.000623	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—TRPC6—brain cancer	9.15e-05	0.000601	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—SMO—brain cancer	8.99e-05	0.000591	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—PTCH1—brain cancer	8.99e-05	0.000591	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—IDH1—brain cancer	8.82e-05	0.00058	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—RELA—brain cancer	8.61e-05	0.000566	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—ERBB2—brain cancer	8.56e-05	0.000562	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—ABR—brain cancer	8.53e-05	0.000561	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—GLI2—brain cancer	8.24e-05	0.000542	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—IL2—brain cancer	7.76e-05	0.00051	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—GLI1—brain cancer	7.75e-05	0.000509	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CCND1—brain cancer	7.56e-05	0.000497	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—VAV1—brain cancer	7.55e-05	0.000496	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CTNNB1—brain cancer	7.49e-05	0.000492	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—SUFU—brain cancer	7.35e-05	0.000483	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—TP53—brain cancer	7.17e-05	0.000471	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—GFAP—brain cancer	7.09e-05	0.000466	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ENO2—brain cancer	6.97e-05	0.000458	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—VAV1—brain cancer	6.85e-05	0.00045	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CYP2C9—brain cancer	6.76e-05	0.000444	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—HEY1—brain cancer	6.72e-05	0.000442	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—VEGFA—brain cancer	6.59e-05	0.000433	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—DLL1—brain cancer	6.59e-05	0.000433	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PIK3CG—brain cancer	6.56e-05	0.000431	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—STAT3—brain cancer	6.53e-05	0.000429	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—MYC—brain cancer	6.06e-05	0.000399	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—EGFR—brain cancer	5.93e-05	0.00039	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—BSG—brain cancer	5.75e-05	0.000378	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—SHH—brain cancer	5.6e-05	0.000368	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PIK3CG—brain cancer	5.55e-05	0.000365	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TRPC6—brain cancer	5.4e-05	0.000355	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—SMO—brain cancer	5.31e-05	0.000349	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PTCH1—brain cancer	5.31e-05	0.000349	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—TP53—brain cancer	4.98e-05	0.000327	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—IDH1—brain cancer	4.94e-05	0.000325	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—PIK3CG—brain cancer	4.79e-05	0.000315	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—PIK3CG—brain cancer	4.35e-05	0.000286	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—NOTCH2—brain cancer	4.25e-05	0.000279	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—VAV1—brain cancer	4.05e-05	0.000266	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ENO2—brain cancer	3.91e-05	0.000257	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—HES1—brain cancer	3.48e-05	0.000229	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—IL2—brain cancer	3.37e-05	0.000222	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PDGFRA—brain cancer	3.31e-05	0.000218	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—SPP1—brain cancer	3.22e-05	0.000211	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PIK3CG—brain cancer	3.2e-05	0.00021	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—IL2—brain cancer	3.06e-05	0.000201	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IRS2—brain cancer	2.91e-05	0.000191	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—APC—brain cancer	2.57e-05	0.000169	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PIK3CG—brain cancer	2.57e-05	0.000169	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—EGFR—brain cancer	2.34e-05	0.000154	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—RELA—brain cancer	2.01e-05	0.000132	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—ERBB2—brain cancer	2e-05	0.000131	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IL2—brain cancer	1.81e-05	0.000119	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PIK3CG—brain cancer	1.79e-05	0.000118	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CCND1—brain cancer	1.76e-05	0.000116	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CTNNB1—brain cancer	1.75e-05	0.000115	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—VEGFA—brain cancer	1.54e-05	0.000101	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—STAT3—brain cancer	1.52e-05	0.0001	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MYC—brain cancer	1.41e-05	9.3e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—EGFR—brain cancer	1.38e-05	9.09e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TP53—brain cancer	1.16e-05	7.63e-05	CbGpPWpGaD
